? CLINICAL TREATMENT UNIT (CTU) AND CLINICAL TRIALS PROCESSING LABORATORY (CTPL) SHARED RESOURCE (CTU/CTPL-SR) An important scientific mission of the OSUCCC is to conduct high quality, cutting edge clinical research for the improved understanding and advancement in treatments of human malignancies. The CTU/CTPL-SR is composed of two different, but intimately related units, namely the Clinical Treatment Unit (CTU) and the Clinical Trials Processing Laboratory (CTPL). The CCSG will only support the CTPL component of the shared resource; support of the CTU component will be entirely from OSUCCC institutional funding, as has been the case for the last two CCSG cycles. The CTU/STPL-SR manages all clinical trial biospecimen collection and processing for samples that are sent externally, and for most clinical trials where samples are being sent to OSUCCC investigator laboratories or shared resources. Key services, in support of all clinical trials needing biospecimen collection, processing and shipping for the CTU/CTPL-SR include consultation on protocol design with regard to correlative specimens, procurement and processing of correlative specimens per protocol specifications developing protocol in-service materials, participating in site initiation visits and protocol implementation meetings, assisting in monitoring visits and audits and shipping specimens internal or external to OSU for analysis. The CTU/CTPL-SR coordinates with other shared resources and departments to address the wide array of biological specimens required for current clinical trials.
The Specific Aims are to: 1) provide a stable, reliable, and cost-effective, state-of-the art unit for conducting early phase clinical trials requiring intense monitoring and/or complex correlative specimen collection; and, 2) provide high-quality, high-volume specimen processing, short-term storage and distribution of biospecimens collected as correlative components of phase I, II and III translational clinical trials. During the current grant period, the CTU/CTP-SR has supported 129 investigators (60% OSUCCC members) from all five OSUCCC research programs, and procured a total of 104,831 specimens from patients enrolled in 729 clinical trials. Also, the CTU/CTPL-SR contributed to 102 publications (36 > 10 impact factor). The CTU/CTPL-SR will continue to be an essential shared resource to facilitate high-quality translational research within the OSUCCC, especially given the current growth plans that include: a) recruitment for both immuno-oncology (Pelotonia Institute of Immuno-Oncology) and translational genomics; and b) commitments to medical oncology, hematology and gynecologic oncology for recruitments and corresponding expectations for increased INDs and trial accruals. The annual budget of the CTU-CTPL-SR is $1,104,344, yet the CCSG request is $126,251. As such, the CTU/CTPL-SR leverages extensive institutional support and seeks only 11.4% support from CCSG funds.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Wang, Yufeng; Dong, Wenjuan; Zhang, Yibo et al. (2018) Dependence of innate lymphoid cell 1 development on NKp46. PLoS Biol 16:e2004867

Showing the most recent 10 out of 2602 publications